Live search
TopFind is fetching the latest matches for your search.
We reviewed 89 live results for bevacizumab biosimilar and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Oncology and Biosimilar.
Source: Biocon Biologics Philippines Inc.
Description
An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients.
Best for
solid tumor treatment, cancer therapy and oncology clinics
Tags
Rating
Source: Pfizer Philippines Inc.
Description
Zirabev is a biosimilar used for oncology supportive care and treatment across multiple cancer types.
Best for
cancer supportive care, oncology treatment and broad-spectrum cancer therapy
Tags
Rating
Source: Amgen
Description
Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment.
Best for
Oncology patients, Metastatic cancer treatment and Subsidized medical care
Rating
| Compare | Bevacizumab Biosimilar | Zirabev (Bevacizumab) | Mvasi (bevacizumab) |
|---|---|---|---|
| Source | Biocon Biologics Philippines Inc. | Pfizer Philippines Inc. | Amgen |
| Description | An oncology biosimilar used in the treatment of various solid tumors, expanding therapeutic options for cancer patients. | Zirabev is a biosimilar used for oncology supportive care and treatment across multiple cancer types. | Mvasi is a biosimilar monoclonal antibody and VEGF inhibitor used in oncology to treat various forms of cancer, including metastatic colorectal cancer (mCRC), non-small cell lung cancer (NSCLC), glioblastoma, and metastatic breast or cervical cancer. It is available as a concentrate for solution for infusion in 100 mg/4 mL and 400 mg/16 mL single-use vials. In Singapore, it is registered with the HSA and listed on the MOH Standard Drug List, providing patients with access to government subsidies and MediShield Life claims for cancer treatment. |
| Best for | solid tumor treatment, cancer therapy and oncology clinics | cancer supportive care, oncology treatment and broad-spectrum cancer therapy | Oncology patients, Metastatic cancer treatment and Subsidized medical care |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
If you want the most balanced option to start with, I recommend:
"Bevacizumab Biosimilar from Biocon Biologics Philippines Inc.."
I picked this because It serves as an essential biosimilar for treating diverse solid tumor types in cancer care.